Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
New Stelara Biosimilars Earn May Listing, Eylea Follow-On Takes Pass Again
Two new biosimilar versions of the anti-IL-12/23p40 antibody Stelara (ustekinumab) will join the NHI price list on May 21, along with a throng of additional dosage forms of existing products, according to the government’s official gazette issued on May 20.…
To read the full story
Related Article
- Multi-Dose Wegovy Pen Now Available in Japan: Novo
July 22, 2025
- Celltrion’s Stelara Biosimilar to Hit Shelves on July 8
July 1, 2025
- Bimzelx Now Available as Single-Injection Option: UCB Japan
May 30, 2025
- Camzyos, Tremfya, Tivdak, and More Now Available in Japan
May 22, 2025
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…